Tildrakizumab effectiveness

After 12 weeks of treatment with the interleukin-23 (IL-23) inhibitor, tildrakizumab (Ilumya), the majority of psoriasis patients can be clear or almost clear of their skin symptoms. People with psoriasis are frequently frustrated over treatments that are ineffective for them, such as tumor necrosis factor biologics, phototherapy, or systemic drugs (such as methotrexate). IL-23 inhibitors, like tildrakizumab, can be an important and effective therapeutic option when patients do not respond to other treatments.